No significant differences were observed between the training and validation groups in terms of age (p = 0.74), histology (p = 0.23), clinical tumor size (p = 0.20), hormone receptor status (p = 0.13), ycN status (p = 0.93), pathological T status (p = 0.28), or pathological N status (p = 0.31). The gene discussed is NR4A1; the disease is neoplasm.